Mathes Company Inc. Takes Position in Eli Lilly and Company (NYSE:LLY)

Mathes Company Inc. bought a new stake in Eli Lilly and Company (NYSE:LLY) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 560 shares of the company’s stock, valued at approximately $432,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Woodard & Co. Asset Management Group Inc. ADV boosted its position in shares of Eli Lilly and Company by 6.0% during the 4th quarter. Woodard & Co. Asset Management Group Inc. ADV now owns 2,211 shares of the company’s stock worth $1,707,000 after acquiring an additional 126 shares in the last quarter. Advanced Asset Management Advisors Inc boosted its holdings in Eli Lilly and Company by 35.5% in the fourth quarter. Advanced Asset Management Advisors Inc now owns 485 shares of the company’s stock valued at $374,000 after purchasing an additional 127 shares in the last quarter. National Mutual Insurance Federation of Agricultural Cooperatives increased its stake in Eli Lilly and Company by 15.3% in the fourth quarter. National Mutual Insurance Federation of Agricultural Cooperatives now owns 19,600 shares of the company’s stock valued at $15,131,000 after purchasing an additional 2,600 shares during the last quarter. AlphaCentric Advisors LLC acquired a new stake in Eli Lilly and Company during the fourth quarter worth approximately $4,740,000. Finally, Principal Financial Group Inc. lifted its position in shares of Eli Lilly and Company by 6.9% during the 4th quarter. Principal Financial Group Inc. now owns 1,291,458 shares of the company’s stock worth $997,006,000 after buying an additional 82,913 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Barclays cut their price target on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research note on Thursday, October 31st. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. Deutsche Bank Aktiengesellschaft cut their price target on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a research report on Monday, November 4th. Redburn Atlantic raised Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. Finally, Wolfe Research initiated coverage on shares of Eli Lilly and Company in a research report on Friday, November 15th. They set an “outperform” rating and a $1,000.00 target price on the stock. Four investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $997.50.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $844.82 on Tuesday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. Eli Lilly and Company has a one year low of $711.40 and a one year high of $972.53. The firm has a market capitalization of $802.01 billion, a P/E ratio of 72.15, a PEG ratio of 1.87 and a beta of 0.42. The company’s fifty day moving average is $794.44 and its two-hundred day moving average is $845.27.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 86.26% and a net margin of 23.51%. Analysts forecast that Eli Lilly and Company will post 23.33 EPS for the current fiscal year.

Eli Lilly and Company announced that its board has authorized a stock buyback plan on Monday, December 9th that permits the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization permits the company to reacquire up to 2% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s board believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be issued a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, February 14th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a yield of 0.71%. Eli Lilly and Company’s payout ratio is currently 44.41%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.